Running interference

Editor’s Note: An earlier version of this story was published in BioCentury on Sept. 25. It has been updated to include reporting about safety and efficacy data that was not included in the original. The update also corrects information about Alnylam’s delivery technologies and the timeline for ESC+ GalNAc to enter the clinic.

Phase III data for Alnylam Pharmaceuticals Inc.’s patisiran resolve one big question: it is now clear that safety signals that have led the company to discontinue or halt previous programs are not intrinsic to its RNAi platform. ...